CN107712900A - Long-chain fat acid glyceride microcapsules and its production method in a kind of feature - Google Patents
Long-chain fat acid glyceride microcapsules and its production method in a kind of feature Download PDFInfo
- Publication number
- CN107712900A CN107712900A CN201710996359.2A CN201710996359A CN107712900A CN 107712900 A CN107712900 A CN 107712900A CN 201710996359 A CN201710996359 A CN 201710996359A CN 107712900 A CN107712900 A CN 107712900A
- Authority
- CN
- China
- Prior art keywords
- oil
- microcapsules
- seed oil
- parts
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 61
- 239000002253 acid Substances 0.000 title claims abstract description 34
- 125000005456 glyceride group Chemical group 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title description 11
- 239000003921 oil Substances 0.000 claims abstract description 99
- 235000019198 oils Nutrition 0.000 claims abstract description 97
- 235000019197 fats Nutrition 0.000 claims abstract description 48
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 239000000463 material Substances 0.000 claims abstract description 38
- 239000008346 aqueous phase Substances 0.000 claims abstract description 37
- 239000012071 phase Substances 0.000 claims abstract description 34
- 241000196324 Embryophyta Species 0.000 claims abstract description 26
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 21
- 239000000944 linseed oil Substances 0.000 claims abstract description 20
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 20
- 239000002738 chelating agent Substances 0.000 claims abstract description 17
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 16
- 239000003240 coconut oil Substances 0.000 claims abstract description 13
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 13
- 241000219226 Acer truncatum Species 0.000 claims abstract description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 240000000924 Lycium carolinianum Species 0.000 claims abstract description 10
- 235000015463 Lycium carolinianum Nutrition 0.000 claims abstract description 10
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims abstract description 10
- 241001135917 Vitellaria paradoxa Species 0.000 claims abstract description 10
- 235000008524 evening primrose extract Nutrition 0.000 claims abstract description 10
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims abstract description 10
- 239000008171 pumpkin seed oil Substances 0.000 claims abstract description 10
- 229940057910 shea butter Drugs 0.000 claims abstract description 10
- 239000010475 evening primrose oil Substances 0.000 claims abstract description 9
- 229940089020 evening primrose oil Drugs 0.000 claims abstract description 9
- 241001300674 Plukenetia volubilis Species 0.000 claims abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 6
- 239000012760 heat stabilizer Substances 0.000 claims abstract description 6
- 239000004519 grease Substances 0.000 claims description 30
- 239000000839 emulsion Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 235000006708 antioxidants Nutrition 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 239000000084 colloidal system Substances 0.000 claims description 16
- 238000009413 insulation Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 238000009418 renovation Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 235000004626 essential fatty acids Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- -1 diglycerine fatty acid ester Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- 235000020429 malt syrup Nutrition 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 235000012054 meals Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 241000736199 Paeonia Species 0.000 claims description 5
- 239000005030 aluminium foil Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- 241000219287 Saponaria Species 0.000 claims description 4
- 235000013325 dietary fiber Nutrition 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- CODAYFPFZXWNLD-UHFFFAOYSA-N 2-hydroxypropanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)C(C)O CODAYFPFZXWNLD-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 3
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 235000019485 Safflower oil Nutrition 0.000 claims description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000011812 mixed powder Substances 0.000 claims description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 235000005713 safflower oil Nutrition 0.000 claims description 3
- 239000003813 safflower oil Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- 235000021324 borage oil Nutrition 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000010638 cranberry seed oil Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 235000004426 flaxseed Nutrition 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 244000237330 gutta percha tree Species 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 150000002978 peroxides Chemical class 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 claims description 2
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 2
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical group C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims description 2
- 229940026509 theaflavin Drugs 0.000 claims description 2
- 235000014620 theaflavin Nutrition 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 102000004407 Lactalbumin Human genes 0.000 claims 1
- 108090000942 Lactalbumin Proteins 0.000 claims 1
- 108010073771 Soybean Proteins Proteins 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000000416 hydrocolloid Substances 0.000 claims 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 1
- 235000020748 rosemary extract Nutrition 0.000 claims 1
- 235000019710 soybean protein Nutrition 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 235000021119 whey protein Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 206010006187 Breast cancer Diseases 0.000 abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 7
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 7
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 206010009944 Colon cancer Diseases 0.000 abstract description 3
- 206010060862 Prostate cancer Diseases 0.000 abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 3
- 230000004888 barrier function Effects 0.000 abstract description 3
- 230000037396 body weight Effects 0.000 abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 210000002889 endothelial cell Anatomy 0.000 abstract description 2
- 230000008944 intestinal immunity Effects 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- 230000036541 health Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000446 fuel Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 150000004667 medium chain fatty acids Chemical class 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 235000020122 reconstituted milk Nutrition 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000021301 omega-3 deficiency Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/27—Xanthan not combined with other microbial gums
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/274—Pullulan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3472—Compounds of undetermined constitution obtained from animals or plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3481—Organic compounds containing oxygen
- A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
- A23L3/3517—Carboxylic acid esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3544—Organic compounds containing hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Fats And Perfumes (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Long-chain fat acid glyceride microcapsules in a kind of feature, it is made up of plant blend oil, wall material, emulsifying agent, oil phase antioxidant, aqueous phase antioxidant and metal-chelator, heat stabilizer and anticaking agent;30 60 parts of plant blend oil is added in 100 parts of microcapsules;The weight of plant blend oil feed components is:Linseed oil 10 20, oil and fat of sacha inchi 13, Purple Perilla Seed Oil 20 30, peony seed oil 13, Seabuckthorm Seed Oil 13, fiery flaxseed oil 5 10, Boxthorn Seed Oil 5 20, acer truncatum seed oil 12, pumpkin seed oil 10 22, evening primrose oil 37, shea butter 15 and coconut oil 16 21.The advantage of the invention is that there is positive role to reducing blood lipid, improvement insulin resistance, protection cardio-vascular endothelial cells function, prevention coronary heart disease, improvement intestinal immunity barrier, control body weight, prevention breast cancer, prostate cancer, straight colon cancer.
Description
Technical field
The microscapsule powder and its production method for being the present invention relates to a kind of functional plants fat or oil composition, belong to food
Manufacture field, more particularly to the answering containing long-chain polyunsaturated fatty acid and medium chain fatty acid of a kind of high fuel load, high stability
Close microcapsules and its production technology.
Background technology
In recent years, proportion improves constantly China resident grease intake in the diet, vegetable oil consumption rapid development.
Newest scientific research finds, in the past few decades between, although people are to saturated fat, such as lard, butter animal fat
Intake constantly reducing, still, the incidence of disease of the chronic disease headed by coronary heart disease, diabetes, cancer, senile dementia is but
Still riseing year after year.In the Omega6 excess in meals and Omega3 deficiency, this can make the reason for one of them is important
Omega6/Omega3 ratio increase, so it is unbalance.China's dietary survey result in 2002 shows most area resident's meals
Middle Omega6/Omega3 ratio is more than 10;China resident eating pattern was progressively westernization in recent years, and this ratio is constantly climbed always
Rise, some areas have met or exceeded U.S. Omega6/Omega3 ratio(>20), this much deviates people from primitive society
Most healthy Omega6/Omega3 ratios 1 in class diet:1.
The increase of Omega6/Omega3 ratios can cause proinflammatory factor in human body(Leukotriene LTB4, thromboxane TXA2 and
The Eicosanoids Omega6 metabolins such as Prostaglandin PGE2)A large amount of synthesis, the disorder of lipid metaboli enzyme and related gene and
The immunization barrier of cell membrane is damaged.Meanwhile Omega6 can also compete cyclooxygenase COX-2 and LOX jointly with Omega3
LOX-5, the metabolic pathway of Omega3 generation anti-inflammatory factors is suppressed, causes inflammatory reaction constantly to aggravate, it is final to induceFertilizer Fat disease, type ii diabetes, atherosclerosis, hypertension, heart disease, NASH, Aging or old silly Slow-witted, arthritis, ulcerative colitis, bronchitis, osteoporosisA series of Metabolic syndrome induced etc. chronic inflammations is levyd
Sick rate rises;Long-term chronic inflammation can more trigger canceration.Level of inflammation, especially inflammatory reaction in " cancer microenvironment " in vivo
Degree it is directly related to the propagation of cancer cell and invasion and attack.Substantial amounts of research in vivo and in vitro has confirmed that long-term intake is high
The cancers such as the edible oil of Omega-6/Omega-3 ratios and breast cancer, oophoroma, prostate cancer, colon cancer are closely related.
At present, both domestic and external learn is carried out to influence of the different Omega3/Omega6 ratios in meals grease to health
A large amount of breakthrough research and discussions, and propose Omega3/Omega6 ratios appropriate in meals, rather than these aliphatic acid
Single concentration, control blood fat, cardiovascular and cerebrovascular diseases, immunological diseases, insulin resistance, obesity, growth of cancer cells, cranial nerve are developed
And visual performance etc. has even more important meaning.So far recommendation ratio of the various countries nutritionist on Omega6/Omega3
Not yet reach common understanding.FAO (Food and Agriculture Organization of the United Nation)(FAO)Recommendation ratio is 5-10:Ratio is suitable in 1, with human breast milk.2001
Chinese Soclety of Nutrition proposes that Omega6/Omega3 suitable proportion should be controlled 4:1 to 6:Between 1.The World Health Organization proposes
Omega6/Omega3 ratios should be less than 6:1.International aliphatic acid and lipid EASD(ISSFAL)Recommend, in order to protect painstaking effort
The daily minimum intake 500g Omega3 of pipe health;Daily recommendation intake is Omega6 4.0g, Omega3 1.9g.And Australia is big
Leah national health and Med Res Co(NHMRC)It is Omega6 10.9g, Omega3 1.4g to recommend daily intake.
Australian National heart foundation(NHFA)Recommend to protect cardiovascular health, daily recommendation Omega3 intake is
2.5g.US Experts ad hoc working group suggest that the dosage standard of adult is that Omega6/Omega3 ratios are 2.3:1.American heart
It is 1 that sick association expert, which recommends suitable Omega6/Omega3 ratios,:1-4:1.Japanese ministry of Health and Welfare proposes Omega6/Omega3
It should be less than 4:1.Since 2010, international nearest scientific research result also confirms the ratio for reducing Omega6/Omega3 again and again
Value, risen rather than just the absolute intake for improving Omega3 in terms of the prevention and treatment of many chronic diseases positive and effective
Effect;And supplement Omega6 merely and give no thought to Omega3 or only take in the Omega3 of trace(Omega6/Omega3 mistakes
It is high)The risk of sugar and fat metabolism, increase coronary heart disease, hyperlipemia, II- patients with type Ⅰ DM, breast cancer etc. may then be upset.
Influence and its Study on Molecular Mechanism report to lipid metabolism in rats, n- are formed according to document different dietary fatty acid
6/n-3 is 1:The triglycerides and cholesterol level in liver and blood can be significantly reduced when 1.Document difference n-6/n-3 is more not
The high fat load meals of saturated fatty acid ratio postprandial glycolipid metabolism is influenceed and antiatherosclerosis Mechanism Study in report, low ratio
Value, especially n-6/n-3 are 1:The occurrence and development of high triglyceride patient's atherosclerosis, and low ratio can be prevented when 1
Compare ratios(N-6/n-3 is 10:1)With middle ratio(N-6/n-3 is 5:1)It more can effectively reduce intracellular cholesteryl and courage is consolidated
Alcohol ester, its antiinflammatory action are more notable.Different proportion n-6/n-3 polyunsaturated fatty acids are formed to mammary gland carcinogenesis in document meals
Pointed out in the influence of development and Study on Molecular Mechanism, n-6/n-3 is formed than being higher than 5:Breast cancer cell can be remarkably promoted when 1
Propagation, and promote effect to increase with n-6/n-3 ratios and strengthen, and n-6/n-3 ratios are equal to and less than 1:When 1, can significantly it press down
The propagation of breast cancer cell processed, and effectively induce its apoptosis.
The conventional edible oil of Chinese residents ordinary meal, such as sunflower oil, peanut oil, safflower oil, corn oil, olive oil,
And small kind health-care oil, in such as wheat-germ oil, sesame oil, rice bran oil, linoleic acid(Omega6)Account for and definitely dominate, and
Alpha-linolenic acid(Omega3)General lack of or missing.As can be seen here, it is common single oil that Omega6/Omega3 ratio is higher
Kind self-defect, only reasonably combined Omega6/Omega3 ratio, reduce Omega6/Omega3 ratio to close to 1:
1, profit and the evil of balanced fatty are only the key that science eats oil.
In addition, the aliphatic acid taken in diet is mainly the long chain fatty acids that carbon number is more than more than 12, and carbon
Medium chain fatty acid intake of the atomicity between 6-12 is seldom.Medium-chain fatty glyceride(MCT)In physical characteristic, digestion
Absorb, be metabolized in vivo etc. and long-chain fat acid glyceride(LCT)It is very different.Works of the LCT in enteral pancreatic lipase
Under, the mono- glyceride of 1 2- and 2 free fatties are hydrolyzed to.It is micro- that 2- monoglycerides and fatty acid emulsifier form bile salt
Micelle and absorbed by small intestinal mucosa cell, by the ester of synthetic glycerine three again in small intestinal mucosa cell, form chylomicron and pass through
Lymphatic system flows into blood, transports adipose tissue, muscle, liver and is further metabolized and utilized.And MCT is in tongue fat
It can be aliphatic acid and glycerine by complete hydrolyzable in the presence of enzyme, gastric lipase, hydrolyze the medium chain fatty acid chain of generation no longer
The ester of synthetic glycerine three, it is most directly to be inhaled by enteron aisle fine hair after bile salt emulsifies in the form of free fatty
Receive, people's blood circulation is entered by portal vein, is transported to liver, into mitochondria after energized by rapid oxidation, it may be said that MCT is several
It can be aoxidized, not accumulated by liver cell completely, it enters the process of mitochondrial membrane and carnitine transfer is limited to unlike LCT
Enzyme, so it absorbs and aoxidized quicker, quick function, the demand to blood glucose is reduced, while fat will not be brought in vivo
Accumulation.
MCT intake can also reduce the level of triglycerides in blood, and improve the metabolism of apolipoprotein, effectively drop
Low LDL-C, and help to reduce the accumulation of interior fat and subcutaneous fat.In a word, MCT has rapid
Absorption decompose produce energy, accelerate lipolysis, pre- preventing obesity the features such as, be a kind of bioactivity lipid, be also considered as
A kind of grease that can lose weight, is more and more applied to the nutritional support of clinical patient, and spy cures food or as health-care oil
Fat is used for daily culinary art.Compared with LCT, MCT can also improve insulin sensitivity, and II- diabetes mellitus types intake MCT can change
The glucose metabolism of kind insulin-mediated, diabetes patient's use is especially suitable for, can effectively improve muscle, liver and adipose tissue
Insulin resistance.But medium chain fatty acid is not essential fatty acid, so long-chain necessary to diet intake also needs to supplement is more
Unrighted acid.Further, since it is solid-state under its normal temperature, this brings inconvenience to daily consumption.
MCT main sources are coconut oil, and its content in coconut oil is up to 66%, and coconut oil accounts for world's grease production
The 1/10 of amount.Also containing abundant MCT in the breast of some animals, as MCT contents are up to 50% in the breast of rabbit and rat.From 19
The fifties in century begins to, and MCT begins to be applied to the treatment of human adipose's malabsorption disease and LCT dysoxidations.At present,
MCT can treat human obesity, insulin resistance, cardiovascular and cerebrovascular diseases etc..
The present invention foundation be:(1)Take into full account reduce Omega6/Omega3 ratios to lipid metaboli, inflammatory reaction, itself
Immune, angiocardiopathy, obesity, diabetes, colitis, and the beneficial effect of breast cancer etc., a variety of health of science collocation are pure
Vegetable fat, make its Omega6:Omega3 is 1-4:1, thus strengthen feature of the essential fatty acid in terms of prevention and treatment of chronic diseases
Effect;(2)MCT introducing compensate for deficiencies of the LCT in terms of energy is quickly provided to a certain extent, and MCT can also promote to grow
The oxidative metabolism of chain fatty acid, avoid its accumulation in the tissue and related Insulin resistance;(3)Table is studied
Bright, the LCT of equivalent is replaced with MCT to be helped to reduce whole body and local fat deposition, is reduced waist-to-hip ratio, is further improved pancreas
Island element resistance;(4)The slightly higher grease of general fusing point(Saturated fatty acid is in the majority, is solid-state under normal temperature), such as MCT and shea butter,
When its microscapsule powder runs into cold-water solution, surface wall material rehydration, but be difficult to discharge, dissolubility is undesirable;And fusing point is relatively low
Grease, as the liquid vegetable oil more than polyunsaturated fatty acid can cause grease easily to be infiltrated from wall material, cause microcapsules
Surface oil is higher, influences its dissolution dispersity and stability(Fat floats after causing rehydration), therefore, can by the two collocation use
So that hard fat fixes liquid oil, embedding efficiency is improved, improves fuel load, strengthening stability;(5)MCT is in normal temperature and low
The state of solidification can be all showed under temperature, the phenomenon that can cause to separate out, be layered directly is mixed with LCT, and microencapsulation technology can
So that effectively grease embedding to be got up, more convenient, stable formulation is converted into, daily supplement is become more convenient and various
Change;(6)Microcapsules on the market or the puzzlement of powdered oil generally existing hot water rehydration rear stability difference, show as oil slick, divide
Layer, have conjunctiva or have granular sensation or sandy sense, fuel load is higher, and oil slick is more serious, and cold water-soluble is bad, it is of the invention then
Solve the above problems.
The content of the invention
What the microcapsule product of the essential fatty acid and medium chain fatty acid that supplement scientific matching simultaneously in the market lacked
Present situation, with reference to both at home and abroad on reducing Omega6/Omega3 ratios to 1-4:1, especially 1:1 can effectively prevent, suppresses or control
The Experimental report for a variety of metabolic syndromes even cancer that inflammation processed triggers, the present inventor complete the present invention, have filled up this
Item product blank.
Microcapsules production method of the present invention solves the lance between existing microcapsules fuel load and rehydration stability
Shield, fuel load is both improved, in turn ensure that microcapsules after rehydration, especially the long-term stability after hot water redissolution, be presented as
Without oil slick, without conjunctiva, without layering, without granular sensation or sandy sense;Low-temperature instant effect might as well simultaneously.
The present invention by plant blend oil, wall material, emulsifying agent, oil phase antioxidant, aqueous phase antioxidant and metal-chelator,
Heat stabilizer and anticaking agent composition;
Added in 100 parts of microcapsulesPlant blend oil30-60 parts;The weight of plant blend oil feed components is:
Linseed oil 10-20, oil and fat of sacha inchi 1-3, Purple Perilla Seed Oil 20-30, peony seed oil 1-3, Seabuckthorm Seed Oil 1-3, fiery flaxseed oil 5-10,
Boxthorn Seed Oil 5-20, acer truncatum seed oil 1-2, pumpkin seed oil 10-22, evening primrose oil 3-7, shea butter 1-5 and coconut oil 16-
21。
It is describedWall materialIt is made up of lactoprotein, maltodextrin, converted starch, malt syrup, wall material renovation agent and hydrophilic colloid,
Its weight is:Lactoprotein 25-35, maltodextrin 7-12, converted starch 3-10, malt syrup 3-8, wall material renovation agent 1-
5th, hydrophilic colloid 0.05-1, water 122-133.
It is describedEmulsifying agent isLecithin, Quillaia saponaria bark extract, list, diglycerine fatty acid ester, diacetyl tartarate list are double sweet
One or more mixtures in grease, stearoyl lactate, sucrose ester, contain 0.4-6 parts in every 100 parts of plant blend oils
Emulsifying agent.
It is describedOil phase antioxidantFor theaflavin, tea polyphenol-palmitate, ascorbyl palmitate, rosemary extraction
One or more of mixtures in thing, natural tocopherol, resist containing 0.09-0.14 part oil phases in every 100 parts of plant blend oils
Oxidant.
It is describedAqueous phase antioxidantFor one or more mixtures in natural complex C, sodium iso-vc, Tea Polyphenols, often
Contain 0.04-1 part aqueous phase antioxidants in 100 parts of microcapsules;
It is describedMetal-chelatorFor in calgon, potassium metapbosphate, sodium pyrophosphate, citric acid, tartaric acid, gluconic acid
One or more mixtures, contain 0.25-1 parts in every 100 parts of microcapsulesMetal-chelator;
It is describedHeat stabilizerFor sodium tripolyphosphate and the mixture of dipotassium hydrogen phosphate, contain 0.5-2 parts in every 100 parts of microcapsulesHeat Stabilizer, the two ratio is 1:4-8;
It is describedAnticaking agentFor silica, contain 0.4-0.7 part anticaking agents in every 100 parts of microcapsules.
In described plant blend oil, the weight of long chain fatty acids is:Saturated fatty acid 6-10 parts are single unsaturated
Aliphatic acid 12-17 parts, Omega6 essential fatty acid 25-36 parts, Omega3 essential fatty acid 19-30 parts;Omega3 and Omega6
The ratio of polyunsaturated fatty acid is 1:2 or 1:1.
In described plant blend oil, long-chain fat acid glyceride is linseed oil, oil and fat of sacha inchi, Purple Perilla Seed Oil, tree peony
It is any in seed oil, Seabuckthorm Seed Oil, fiery flaxseed oil, Boxthorn Seed Oil, acer truncatum seed oil, pumpkin seed oil, evening primrose oil, shea butter
Combination;Also can be selected algae oil, walnut oil, borage oil, safflower oil, hippophae rhamnoides fruit oil, Seabuckthorm Seed Oil, Cranberry seed oil, pine-seed oil,
One or more of mixtures in samara oil, gamma-Linolenic acid, CLA, grape-kernel oil, eucommia ulmoides seed oil.
In described plant blend oil, medium-chain fatty glyceride is coconut oil.
The weight of each raw material components is in described plant blend oil:Linseed oil 15, oil and fat of sacha inchi 2, purple perilla
Seed oil 23, peony seed oil 2, Seabuckthorm Seed Oil 3, fiery flaxseed oil 8, Boxthorn Seed Oil 10, acer truncatum seed oil 1, pumpkin seed oil 12, oenothera biennis
Oil 5, shea butter 3, coconut oil 17.
Acid value≤1 of described grease(KOH mg/g), peroxide value≤0.13(G/100g, with buttermeter).
The preparation method of plant blend oil is as follows:Under nitrogen protective condition, each grease is proportionally added into mixing
In tank, at 35-40 °C of temperature, condition of normal pressure, stirred 20-60 minutes with 60r/min speed, filtering, planted after standing
Thing ready-mixed oil.
Wall material renovation agent in the wall material is the dietary fiber of small molecule, lactose, sucrose, trehalose, L-arabinose,
One or more mixing in D-sorbite, xylitol;Dietary fiber be resistant dextrin, inulin, stachyose, FOS,
Any combination of galactooligosaccharide, oligoisomaltose;Hydrophilic colloid in the wall material is xanthans, flaxseed gum, Pu Lu
One or more mixing of blue polysaccharide, Arabic gum.
Processing method is:
It is prepared by aqueous phase:First hydrophilic colloid, heat preservation for standby use are fully dissolved with 70 °C of part hot water;With part aqueous solution metal-chelating
Agent, it is stand-by;With aqueous phase tank, lactoprotein, converted starch are charged first in 50-65 °C of hot water, are incubated, stirring is allowed to completely molten
Solution, maltodextrin, malt syrup and wall material renovation agent are added, 50-65 °C of insulation, being sufficiently stirred mixes wall material dissolving, adds
Enter pre- solvent hydrophilic colloid;Then it is cooled to 45-55 °C;Finally pre- solvent metal-chelator and aqueous phase antioxidant are added
Enter into aqueous phase tank, obtain aqueous phase;
It is prepared by oil phase:First vegetable oil is reconciled and is added to oil phase tank, 50-65 °C is slowly heated to, first adds emulsifying agent, insulation makes
Emulsifying agent is completely dissolved, and is then cooled to 40 °C, adds oil phase antioxidant, and stirring is allowed to fully dissolve, and obtains oil phase;
The preparation of colostric fluid:Aqueous phase is first pumped into emulsion tank, 48-52 °C of insulation, while opens stirring and high speed shear, then
Oil phase is slowly added into emulsion tank, cuts 20-40 minutes at a high speed, and keeps -20--50mPa vacuum, obtains colostric fluid;
It is prepared by emulsion:Using secondary pressure homogenizer to colostric fluid carry out homogeneous, homogeneous 2-3 times, homogenization pressure 40-65Pa,
Obtain emulsion;
Sterilizing:Using ultra high temperature short time sterilization machine to step(4)Obtained emulsion sterilizes 10-15s under 108-135 °C, discharging
Temperature is 60-70 °C;
Spray drying:EAT is 165-180 °C, and leaving air temp is 85-90 °C, then passes through fluid bed and gathers again, obtains micro-
Capsule powders;
Mixed powder sieving:Anticaking agent is added to step(6)In obtained microscapsule powder, it is well mixed, crosses 20 mesh or 40 mesh shake
Dynamic sieve, obtained microcapsules;
Packaging:By step(7)Obtained microcapsules, load PE inner bags, first vacuumize, backfill nitrogen afterwards, by metal detection
After instrument, load aluminium foil bag, obtain finished product;
Can be by step(8)Granule or capsule is made using conventional formulation method in gained microcapsules.
The step(1)Middle amount of water is calculated by emulsion solid content 30-45%;Temperature control is at 50-60 ° in homogenizing process
C;Material after sterilizing temperature to be painted is 50-60 °C;Spray drying tower is upper air-out Spray Grain-make Drier, and atomizer is pressure
Power atomizer;Material after sterilizing is forced into spray drying tower by high-pressure pump, and high pressure pump pressure is 8-15mPa;For fluid bed
Temperature is 40-70 °C.
The advantage of the invention is that:
(1) the advantages of grease of the invention combines long-chain polyunsaturated fatty acid and medium chain fatty acid, can be with comprehensive offer
Have the healthy grease of feature and nutrition concurrently, especially to reducing blood lipid, improve insulin resistance, protection cardio-vascular endothelial cells work(
, can prevent coronary heart disease, improvement intestinal immunity barrier, control body weight, prevention breast cancer, prostate cancer, straight colon cancer has product
Pole acts on.
(2) grease of the present invention is the vegetable oil by mediation, solve in general Vegetable Oils Omega3 and
The unsound problem of Omega6 polyunsaturated fatty acid ratios, makes the ratio of the two reach 1:1-4, closer to Chronic disease prevention and
Cancer, protect the proper ratio required for health.
(3) microcapsule raw auxiliary material of the invention is food additives, though it is high in fuel load, and majority is how unsaturated fat
Fat acid esters, but be free of chemical synthesis antioxidant(Such as TBHQ, BHA, BHT), but natural composite antioxidant is selected, improve production
The product shelf time limit.
(4) in order to solve the problems, such as high easy oil slick after carrying oil microcapsule rehydration, it is excellent that present invention innovation employs emulsifiability
Natural phosphatidyl choline more and the natural component as food additives new varieties --- Quillaia saponaria bark extract, wherein, lecithin is not
Only play a part of stable emulsifying oil droplet, itself be also it is a kind of well protection brain and nervous system health activity into
Point;Traditional microcapsules are avoided to chemical synthesis emulsifying agent, such as single, bis-fatty acid glyceride, sucrose ester, polyglycerol fatty acid
The dependence of ester, stearoyl lactate, Tween 80 etc..Numerous studies have shown that it is eaten for a long time containing chemical synthesis emulsifying agent
Processed food, can trigger chronic enteritis, cause gut barrier dysfunction, the digestion and immunologic function to human body are unfavorable.
(5) natural the compound emulsifying agent lecithin and Quillaia saponaria bark extract that use of the present invention, and using casein sodium as
Main compound wall materialses can improve the high hydrophily for carrying oil microcapsule cyst wall, make particle small and be distributed homogeneous;Thus meeting it
To low temperature particularly cold water(25°C)Can also fully be discharged when reconstituting, rapid dispersion, after product rehydration emulsion particle diameter it is small and
It is homogeneous, reduce or prevent fatty floating, it is not stratified, without conjunctiva;Avoiding traditional microcapsules needs hot water just to be filled as thermal source
Point dissolving and the deficiency of release grease, the characteristics of meeting hot and cold water and molten, rapid dispersion.
(6) present invention uses casein sodium and converted starch as main wall material, while with the addition of wall material renovation agent, i.e., small
The inserts of molecule, including dietary fiber(Resistant dextrin, inulin, stachyose etc.), small sugar(Such as lactose, sucrose, trehalose, L-
Arabinose), sugar alcohol(D-sorbite, xylitol)Deng one or more compositions, it can cooperate with full together with grease
Sufficient consumer to control blood-fat and blood sugar and the needs of body weight, strengthen the compactness of wall material, improve the glass transition of wall material by and can
Temperature, moreover it is possible to lift mouthfeel and taste.
(7) hydrophilic colloid that the present invention is added(Xanthans etc.)Cyst wall compactness, the resistance of microcapsules can further be improved
Oxygen, water preventing ability;Can also increase simultaneously it is high-pressure homogeneous after the obtained viscosity of emulsion, for forming big in spray-drying process
Droplet is highly beneficial, it is possible thereby to obtain larger granularity, increases the particle diameter of emulsion after rehydration, improves microscapsule powder
Mobility and instant capacity;Simultaneously because xanthans has certain thickening power, emulsion stability after rehydration can be improved, reduced
Coalescence or the possibility to float occur for reconstituted milk.
(8) microscapsule powder of the invention can realize hot water or cold water and molten, and dissolving is rapid, hot water(85°C)Reconstituting also can be real
Existing fabulous stability, reconstituted milk state after not stratified, fat-free floating, dissolving is homogeneous, without sand type and mellow in taste.
(9) advantage of the invention with most of microcapsules manufacture crafts also resides in, and technique involved in the present invention is without height
Warm process, from the aqueous phase of pretreatment stage and the preparation of oil phase, air intake and leaving air temp to spray drying are all controlled relative
Low level, at utmost avoid the destruction of the Oxidation of Fat and Oils and active component of high-temperature induction;It it also avoid wall material and U.S. occur
Maillard reaction.
(10) of the present invention is upper air-out spray granulating and drying tower, i.e.,:Particle after the atomization drying quilt in tower
Upward air inducing traction, meets with the drop of rear atomization and the fine powder of other suspensions, soaks again, sticks into bulky grain reunion
Body, re-dry, repeated multiple times on this basis, is increased to unit weight and is enough to fall it, and thus the microscapsule powder of gained is thin
Powder ratio is small, and granularity is big and homogeneous, has been not easy electrostatic, all favourable to follow-up mixed powder, sieve powder, packaging.
(11) microcapsules of the present invention are excellent health product raw materials, can be widely applied to health products, dairy products, consolidate
Body beverage, capsule etc..
Figure of description
Fig. 1 is present invention process flow chart.
Embodiment
Formed because the microcapsules designed by the present invention are reconciled by various plants oil, by kind, the place of production, extraction process etc.
Influence, the Fatty acid compositions of every kind of grease have fluctuation, therefore supplied materials should be detected before manufacture, to ensure ready-mixed oil
Omega3 and Omega6 is optimal proportion 1 in grease:1-2.
Embodiment 1.
(1) long-chain fat acid glyceride microcapsules in a kind of feature, its grease by the component compatibility of following parts by weight and
Into:Linseed oil 15, oil and fat of sacha inchi 2, Purple Perilla Seed Oil 23, peony seed oil 2, Seabuckthorm Seed Oil 3, fiery flaxseed oil 8, Boxthorn Seed Oil 10,
Acer truncatum seed oil 1, pumpkin seed oil 12, evening primrose oil 5, shea butter 3, coconut oil 17;Oil wherein after the mediation of the present embodiment
Contain 28.1 parts of Omega3 essential fatty acids, 28.2 parts of Omega6 essential fatty acids in fat, the two ratio is 1:1.
(2) under nitrogen protection, the good grease of above compatibility is added into blending tank, in 35-40 °C of temperature, condition of normal pressure
Under, stirred 40 minutes with 60r/min speed, obtained after filtering.
(3) long-chain fat acid glyceride microcapsules in a kind of feature, in terms of weight part ratio, the raw material proportioning of the microcapsules
It is as follows:
(4) long-chain fat acid glyceride microcapsule preparation method is as follows in a kind of feature:
1st, prepared by aqueous phase:First hydrophilic colloid, heat preservation for standby use are fully dissolved with 70 °C of part hot water;With part aqueous solution metal-chelating
Agent, it is stand-by;With aqueous phase tank, lactoprotein, converted starch are charged first in 65 °C of hot water, are incubated, stirring is allowed to be completely dissolved, then
Maltodextrin, malt syrup and wall material renovation agent are added, 65 °C of insulations, being sufficiently stirred mixes wall material dissolving, adds pre- solvent
Hydrophilic colloid, be then cooled to 50 °C;Finally metal-chelator and aqueous phase antioxidant are added in aqueous phase tank, obtain water
Phase.
2nd, prepared by oil phase:Grease is first added to oil phase tank, is slowly heated to 60 °C, first adds emulsifying agent, insulation makes breast
Agent is completely dissolved, and is then cooled to 40 °C and is added oil phase antioxidant, stirring is allowed to fully dissolve, and obtains oil phase.
3rd, the preparation of colostric fluid:Aqueous phase is first pumped into emulsion tank, 50 °C of insulations, opens stirring and high speed shear, then
Oil phase is slowly added into emulsion tank, cut at a high speed 40 minutes, and keeps certain vacuum degree, obtains colostric fluid.
4th, homogeneous:Homogeneous is carried out to colostric fluid using secondary pressure homogenizer, homogeneous 2 times, homogenization pressure 53MPa, obtained
To emulsion.
5th, sterilize:Sterilized using the emulsion that ultra high temperature short time sterilization machine obtains to step 4 under 110 °C 15s.
6th, it is spray-dried:EAT is 175 °C, and leaving air temp is 84 °C, then passes through fluid bed and gathers again, obtains micro- glue
Capsule powder.
7th, powder sieving is mixed:Silica is added in the microscapsule powder that step 6 obtains, be well mixed, crossed 20 mesh and shake
Dynamic sieve.
8th, pack:The microcapsules obtained by step 7, load PE inner bags, first vacuumize, backfill nitrogen afterwards, by metal
After survey meter, load aluminium foil bag, obtain finished product.
Embodiment 2.
(1) long-chain fat acid glyceride microcapsules in a kind of feature, its grease by the component compatibility of following parts by weight and
Into:Linseed oil 12, Purple Perilla Seed Oil 16, Seabuckthorm Seed Oil 2, fiery flaxseed oil 5, Boxthorn Seed Oil 16, pumpkin seed oil 18, acer truncatum seed oil
2nd, the required fat of Omega3 is contained in the grease after evening primrose oil 4, shea butter 4, and coconut oil 21, the wherein mediation of the present embodiment
20.4 parts of fat acid, 30.8 parts of Omega6 essential fatty acids, the two ratio is 1:1.5.
(2) under nitrogen protection, the good grease of above compatibility is added into blending tank, in 35-40 °C of temperature, condition of normal pressure
Under, stirred 30 minutes with 60r/min speed, obtained after filtering.
(3) long-chain fat acid glyceride microcapsules in a kind of feature, in terms of weight part ratio, the raw material proportioning of the microcapsules
It is as follows:
(4) long-chain fat acid glyceride microcapsule preparation method is as follows in a kind of feature:
1st, prepared by aqueous phase:First hydrophilic colloid, heat preservation for standby use are fully dissolved with 70 °C of part hot water;With part aqueous solution metal-chelating
Agent, it is stand-by;With aqueous phase tank, lactoprotein, converted starch are charged first in 65 °C of hot water, are incubated, stirring is allowed to be completely dissolved, then
Maltodextrin, malt syrup and wall material renovation agent are added, 65 °C of insulations, being sufficiently stirred mixes wall material dissolving, is then cooled to
50°C;Finally pre- solvent hydrophilic colloid, metal-chelator and aqueous phase antioxidant are added in aqueous phase tank, obtain aqueous phase.
2nd, prepared by oil phase:Grease is first added to oil phase tank, is slowly heated to 60 °C, first adds emulsifying agent, insulation makes breast
Agent is completely dissolved, and is then cooled to 40 °C and is added oil phase antioxidant, stirring is allowed to fully dissolve, and obtains oil phase.
3rd, the preparation of colostric fluid:Aqueous phase is first pumped into emulsion tank, 50 °C of insulations, opens stirring and high speed shear, then
Oil phase is slowly added into emulsion tank, cut at a high speed 40 minutes, and keeps certain vacuum degree, obtains colostric fluid.
4th, homogeneous:Homogeneous is carried out to colostric fluid using secondary pressure homogenizer, homogeneous 2 times, homogenization pressure 55MPa, obtained
To emulsion.
5th, sterilize:Sterilized using the emulsion that ultra high temperature short time sterilization machine obtains to step 4 under 109 °C 15s.
6th, it is spray-dried:EAT is 170 °C, and leaving air temp is 85 °C, then passes through fluid bed and gathers again, obtains micro- glue
Capsule powder.
7th, powder sieving is mixed:Silica is added in the microscapsule powder that step 6 obtains, be well mixed, crossed 40 mesh and shake
Dynamic sieve.
8th, pack:The microcapsules obtained by step 7, load PE inner bags, first vacuumize, backfill nitrogen afterwards, by metal
After survey meter, load aluminium foil bag, obtain finished product.
Embodiment 3.
Long-chain fat acid glyceride microcapsules in a kind of feature, its grease are formed by the component compatibility of following parts by weight:
Linseed oil 10, Purple Perilla Seed Oil 15, Seabuckthorm Seed Oil 1, fiery flaxseed oil 5, Boxthorn Seed Oil 20, pumpkin seed oil 22, acer truncatum seed oil 1,
Contain the required fat of Omega3 in grease after evening primrose oil 47, shea butter 1, and coconut oil 16, the wherein mediation of the present embodiment
18.8 parts of fat acid, 36.7 parts of Omega6 essential fatty acids, the two ratio is 1:2.Under nitrogen protection, by the good oil of above compatibility
Fat adds blending tank, at 35-40 °C of temperature, condition of normal pressure, is stirred 20 minutes with 60r/min speed, is obtained after filtering.
Long-chain fat acid glyceride microcapsules in a kind of feature, in terms of weight part ratio, the raw material proportioning of the microcapsules is such as
Under:
Long-chain fat acid glyceride microcapsule preparation method is as follows in a kind of feature:
1st, prepared by aqueous phase:First hydrophilic colloid, heat preservation for standby use are fully dissolved with 70 °C of part hot water;With part aqueous solution metal-chelating
Agent, it is stand-by;With aqueous phase tank, lactoprotein, converted starch are charged first in 63 °C of hot water, are incubated, stirring is allowed to be completely dissolved, then
Maltodextrin, malt syrup and wall material renovation agent are added, 60 °C of insulations, being sufficiently stirred mixes wall material dissolving, adds pre- solvent
Hydrophilic colloid;Then 55 °C are cooled to;Pre- solvent metal-chelator and aqueous phase antioxidant are finally added to aqueous phase tank
In, obtain aqueous phase.
2nd, prepared by oil phase:Grease is first added to oil phase tank, is slowly heated to 65 °C, first adds emulsifying agent, insulation makes breast
Agent is completely dissolved, and is then cooled to 40 °C and is added oil phase antioxidant, stirring is allowed to fully dissolve, and obtains oil phase.
3rd, the preparation of colostric fluid:Aqueous phase is first pumped into emulsion tank, 55 °C of insulations, opens stirring and high speed shear, then
Oil phase is slowly added into emulsion tank, cut at a high speed 30 minutes, and keeps certain vacuum degree, obtains colostric fluid.
4th, homogeneous:Homogeneous is carried out to colostric fluid using secondary pressure homogenizer, homogeneous 2 times, homogenization pressure 48MPa, obtained
To emulsion.
5th, sterilize:Sterilized using the emulsion that ultra high temperature short time sterilization machine obtains to step 4 under 108 °C 15s.
6th, it is spray-dried:EAT is 165 °C, and leaving air temp is 85 °C, then passes through fluid bed and gathers again, obtains micro- glue
Capsule powder.
7th, powder sieving is mixed:Silica is added in the microscapsule powder that step 6 obtains, be well mixed, crossed 40 mesh and shake
Dynamic sieve.
8th, pack:The microcapsules obtained by step 7, load PE inner bags, first vacuumize, backfill nitrogen afterwards, by metal
After survey meter, load aluminium foil bag, obtain finished product.
Claims (10)
1. long-chain fat acid glyceride microcapsules in a kind of feature, it is characterised in that it is by plant blend oil, wall material, emulsification
Agent, oil phase antioxidant, aqueous phase antioxidant and metal-chelator, heat stabilizer and anticaking agent composition;
Plant blend oil 30-60 parts are added in 100 parts of microcapsules;The weight of plant blend oil feed components is:
Linseed oil 10-20, oil and fat of sacha inchi 1-3, Purple Perilla Seed Oil 20-30, peony seed oil 1-3, Seabuckthorm Seed Oil 1-3, fiery flaxseed oil 5-10,
Boxthorn Seed Oil 5-20, acer truncatum seed oil 1-2, pumpkin seed oil 10-22, evening primrose oil 3-7, shea butter 1-5 and coconut oil 16-
21;
The wall material is made up of lactoprotein, maltodextrin, converted starch, malt syrup, wall material renovation agent and hydrophilic colloid, and its is heavy
Amount part, which matches, is:Lactoprotein 25-35, maltodextrin 7-12, converted starch 3-10, malt syrup 3-8, wall material renovation agent 1-5, parent
Hydrocolloid 0.05-1, water 122-133;
The emulsifying agent be lecithin, Quillaia saponaria bark extract, list, diglycerine fatty acid ester, diacetyl tartarate list double glyceride,
One or more mixtures in stearoyl lactate, sucrose ester, emulsified containing 0.4-6 parts in every 100 parts of plant blend oils
Agent;
The oil phase antioxidant is theaflavin, tea polyphenol-palmitate, ascorbyl palmitate, Rosmarinus officinalis extract, day
One or more of mixtures in right tocopherol, it is anti-oxidant containing 0.09-0.14 part oil phases in every 100 parts of plant blend oils
Agent;
The aqueous phase antioxidant is natural complex C, one or more mixtures in sodium iso-vc, Tea Polyphenols, every 100 parts
Contain 0.04-1 part aqueous phase antioxidants in microcapsules;
The metal-chelator is in calgon, potassium metapbosphate, sodium pyrophosphate, citric acid, tartaric acid, gluconic acid
One or more mixtures, contain 0.25-1 part metal-chelators in every 100 parts of microcapsules;
The heat stabilizer is the mixture of sodium tripolyphosphate and dipotassium hydrogen phosphate, contains 0.5-2 parts heat in every 100 parts of microcapsules
Stabilizer, the two ratio are 1:4-8;
The anticaking agent is silica, and 0.4-0.7 part anticaking agents are contained in every 100 parts of microcapsules.
2. long-chain fat acid glyceride microcapsules in a kind of feature according to claim 1, it is characterised in that:Described
In plant blend oil, the weight of long chain fatty acids is:Saturated fatty acid 6-10 parts, monounsaturated fatty acids 12-17 parts,
Omega6 essential fatty acid 25-36 parts, Omega3 essential fatty acid 19-30 parts;Omega3 and Omega6 polyunsaturated fatty acids
Ratio be 1:2 or 1:1.
3. long-chain fat acid glyceride microcapsules in a kind of feature according to claim 1 or 2, it is characterised in that:Institute
In the plant blend oil stated, long-chain fat acid glyceride is linseed oil, oil and fat of sacha inchi, Purple Perilla Seed Oil, peony seed oil, seabuckthorn seeds
Any combination in oily, fiery flaxseed oil, Boxthorn Seed Oil, acer truncatum seed oil, pumpkin seed oil, evening primrose oil, shea butter;It is also optional
With algae oil, walnut oil, borage oil, safflower oil, hippophae rhamnoides fruit oil, Seabuckthorm Seed Oil, Cranberry seed oil, pine-seed oil, samara oil, γ-
One or more of mixtures in leukotrienes, CLA, grape-kernel oil, eucommia ulmoides seed oil.
4. long-chain fat acid glyceride microcapsules in a kind of feature according to claim 1, it is characterised in that:Described
In plant blend oil, medium-chain fatty glyceride is coconut oil.
5. long-chain fat acid glyceride microcapsules in a kind of feature according to claim 1 or 2, it is characterised in that:Institute
The weight of each raw material components is in the plant blend oil stated:Linseed oil 15, oil and fat of sacha inchi 2, Purple Perilla Seed Oil 23, tree peony
Seed oil 2, Seabuckthorm Seed Oil 3, fiery flaxseed oil 8, Boxthorn Seed Oil 10, acer truncatum seed oil 1, pumpkin seed oil 12, evening primrose oil 5, the wooden fruit of breast
Oil 3, coconut oil 17.
6. the plant blend oil of the scientific matching according to Claims 2 or 3, it is characterised in that the acid value of described grease≤
1 (KOH mg/g), peroxide value≤0.13(G/100g, with buttermeter).
7. long-chain fat acid glyceride microcapsules in a kind of feature according to claim 1 or 2, it is characterised in that plant
The preparation method of ready-mixed oil is as follows:Under nitrogen protective condition, each grease is proportionally added into blending tank, in temperature
35-40 °C, under condition of normal pressure, stirred 20-60 minutes with 60r/min speed, filtering, plant blend oil is obtained after standing.
8. according to claim 1, the lactoprotein in described wall material is that casein sodium, whey protein isolate, lactalbumin are dense
One or more mixtures in contracting thing or soybean protein isolate;Wall material renovation agent in the wall material is the meals of small molecule
One or more mixing in fiber, lactose, sucrose, trehalose, L-arabinose, D-sorbite, xylitol;Dietary fiber
For resistant dextrin, inulin, stachyose, FOS, galactooligosaccharide, oligoisomaltose any combination;In the wall material
Hydrophilic colloid be xanthans, flaxseed gum, pulullan polysaccharide, Arabic gum one or more mixing.
9. long-chain fat acid glyceride microcapsules in a kind of feature according to claim 1, it is characterised in that processing side
Method is:
It is prepared by aqueous phase:First hydrophilic colloid, heat preservation for standby use are fully dissolved with 70 °C of part hot water;With part aqueous solution metal-chelating
Agent, it is stand-by;With aqueous phase tank, lactoprotein, converted starch are charged first in 50-65 °C of hot water, are incubated, stirring is allowed to completely molten
Solution, maltodextrin, malt syrup and wall material renovation agent are added, 50-65 °C of insulation, being sufficiently stirred mixes wall material dissolving, adds
Enter pre- solvent hydrophilic colloid;Then it is cooled to 45-55 °C;Finally pre- solvent metal-chelator and aqueous phase antioxidant are added
Enter into aqueous phase tank, obtain aqueous phase;
It is prepared by oil phase:First vegetable oil is reconciled and is added to oil phase tank, 50-65 °C is slowly heated to, first adds emulsifying agent, insulation makes
Emulsifying agent is completely dissolved, and is then cooled to 40 °C, adds oil phase antioxidant, and stirring is allowed to fully dissolve, and obtains oil phase;
The preparation of colostric fluid:Aqueous phase is first pumped into emulsion tank, 48-52 °C of insulation, while opens stirring and high speed shear, then
Oil phase is slowly added into emulsion tank, cuts 20-40 minutes at a high speed, and keeps -20--50mPa vacuum, obtains colostric fluid;
It is prepared by emulsion:Using secondary pressure homogenizer to colostric fluid carry out homogeneous, homogeneous 2-3 times, homogenization pressure 40-65Pa,
Obtain emulsion;
Sterilizing:Using ultra high temperature short time sterilization machine to step(4)Obtained emulsion sterilizes 10-15s under 108-135 °C, discharging
Temperature is 60-70 °C;
Spray drying:EAT is 165-180 °C, and leaving air temp is 85-90 °C, then passes through fluid bed and gathers again, obtains micro-
Capsule powders;
Mixed powder sieving:Anticaking agent is added to step(6)In obtained microscapsule powder, it is well mixed, crosses 20 mesh or 40 mesh shake
Dynamic sieve, obtained microcapsules;
Packaging:By step(7)Obtained microcapsules, load PE inner bags, first vacuumize, backfill nitrogen afterwards, by metal detection
After instrument, load aluminium foil bag, obtain finished product;
Can be by step(8)Granule or capsule is made using conventional formulation method in gained microcapsules.
10. long-chain fat acid glyceride microcapsules in a kind of feature described in claim 9, it is characterised in that the step
(1)Middle amount of water is calculated by emulsion solid content 30-45%;Temperature control is at 50-60 °C in homogenizing process;Thing after sterilizing
It is 50-60 °C to expect temperature to be painted;Spray drying tower is upper air-out Spray Grain-make Drier, and atomizer is pressure atomizer;Go out
Material after bacterium is forced into spray drying tower by high-pressure pump, and high pressure pump pressure is 8-15mPa;It it is 40-70 ° for fluidized-bed temperature
C。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710996359.2A CN107712900A (en) | 2017-10-24 | 2017-10-24 | Long-chain fat acid glyceride microcapsules and its production method in a kind of feature |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710996359.2A CN107712900A (en) | 2017-10-24 | 2017-10-24 | Long-chain fat acid glyceride microcapsules and its production method in a kind of feature |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107712900A true CN107712900A (en) | 2018-02-23 |
Family
ID=61213329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710996359.2A Pending CN107712900A (en) | 2017-10-24 | 2017-10-24 | Long-chain fat acid glyceride microcapsules and its production method in a kind of feature |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107712900A (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108578370A (en) * | 2018-04-19 | 2018-09-28 | 大连医诺生物股份有限公司 | Lutein/lutein ester particle and preparation method thereof |
CN108967987A (en) * | 2018-06-20 | 2018-12-11 | 漯河双汇生物工程技术有限公司 | A kind of garlicky essence of blending type and preparation method thereof |
CN109007838A (en) * | 2018-07-25 | 2018-12-18 | 长沙浩然医疗科技有限公司 | A kind of functional health care food and preparation method thereof of lecithin norcholesterol |
CN109090360A (en) * | 2018-08-10 | 2018-12-28 | 湖南普菲克生物科技有限公司 | A kind of coconut oil micro-capsule fatty powder and the application in the big perinatal period daily ration of sow |
CN109259228A (en) * | 2018-11-12 | 2019-01-25 | 陕西海斯夫生物工程有限公司 | A kind of raw ketone weight-reducing microcapsule powder of full element and preparation method thereof |
CN109315786A (en) * | 2018-11-26 | 2019-02-12 | 荣海生物科技有限公司 | A kind of MLCT microcapsules and preparation method thereof containing small-molecular peptides |
CN109380700A (en) * | 2018-11-08 | 2019-02-26 | 天津科技大学 | A kind of galic essential oil microcapsules and preparation method thereof |
CN109566772A (en) * | 2018-11-30 | 2019-04-05 | 北京诺康达医药科技股份有限公司 | Micro mist and preparation method thereof containing fish oil linseed oil safflower oil |
CN109924488A (en) * | 2019-04-25 | 2019-06-25 | 璐炬. | A kind of acer truncatum seed and linseed compound cryosar Ultramicro-powder microcapsule preparation method |
CN110419736A (en) * | 2019-04-25 | 2019-11-08 | 河北康睿达脂质有限公司 | A kind of middle backbone lipid composition preparation method of mammary gland disease nutrition treatment |
CN111150087A (en) * | 2019-12-31 | 2020-05-15 | 西昌市正中食品有限公司 | Embedding wall material and microcapsule tartary buckwheat extract and preparation process thereof |
CN111357835A (en) * | 2020-03-03 | 2020-07-03 | 中国食品发酵工业研究院有限公司 | Sea buckthorn seed oil microcapsule rich in dietary fiber and preparation method thereof |
CN111466448A (en) * | 2020-04-14 | 2020-07-31 | 劲牌持正堂药业有限公司 | Preparation method of high-water-solubility fructus cannabis extract |
CN111925771A (en) * | 2020-08-18 | 2020-11-13 | 福建农林大学 | Pressure-responsive room-temperature curing wood adhesive and preparation method thereof |
CN112075630A (en) * | 2020-08-24 | 2020-12-15 | 武汉星辰现代生物工程有限公司 | Natural carotene microcapsule and preparation method thereof |
CN112450285A (en) * | 2020-10-21 | 2021-03-09 | 武汉轻工大学 | Oxidation-resistant pumpkin seed oil capsule and preparation method thereof |
CN112716014A (en) * | 2020-12-22 | 2021-04-30 | 浙江远大生物科技有限公司 | Preparation method of unsaturated fatty acid microcapsule |
CN112913934A (en) * | 2021-03-24 | 2021-06-08 | 固始县豫申粮油工贸有限公司 | Preparation method of powdered medium-long carbon chain triglyceride rice oil |
CN113303463A (en) * | 2021-05-31 | 2021-08-27 | 苏州品宝食品有限公司 | Method for manufacturing healthy medium chain triglyceride powder based on microcapsule technology |
US11110140B1 (en) * | 2020-04-10 | 2021-09-07 | Daniel Lilly | Medicinal food products and methods for producing said products |
CN114271496A (en) * | 2021-12-15 | 2022-04-05 | 河北东康乳业有限公司 | Diabetes type vegetable oil diglyceride microcapsule fat powder and preparation method thereof |
CN114287624A (en) * | 2021-12-27 | 2022-04-08 | 黑龙江八一农垦大学 | Composite protein emulsion gel and production method thereof |
CN114304689A (en) * | 2022-02-10 | 2022-04-12 | 宝得瑞(湖北)健康产业有限公司 | Preparation method of high-oil-loading microcapsule powder without adding synthetic emulsifier |
CN114521655A (en) * | 2022-01-27 | 2022-05-24 | 华南理工大学 | Intestinal tract probiotic promoter containing medium-long chain triglyceride in almond oil and preparation method and application thereof |
CN115337880A (en) * | 2022-07-15 | 2022-11-15 | 纽斯葆广赛(广东)生物科技股份有限公司 | Pumpkin seed oil microcapsule and preparation method and application thereof |
CN113812552B (en) * | 2021-09-01 | 2023-12-26 | 江南大学 | Total nutrient solid beverage |
WO2024076917A1 (en) * | 2022-10-03 | 2024-04-11 | Innovative Flours, Llc | Protein-complexed mct oil, method of manufacture, and food products made therefrom |
WO2024076911A1 (en) * | 2022-10-03 | 2024-04-11 | Innovative Flours, Llc | Composite flour, method of manufacture, and food products made therefrom |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269310A (en) * | 2008-05-06 | 2008-09-24 | 大连赛诺微囊技术有限公司 | Method for preparing cold water dispersion type microcapsule powder |
CN101647512A (en) * | 2009-06-17 | 2010-02-17 | 新奥(厦门)农牧发展有限公司 | Polyphyly fat mixture for feeding animals and microcapsule applying mixture |
WO2011026612A1 (en) * | 2009-09-02 | 2011-03-10 | Lipofoods, S.L. | Microcapsules containing salts for food products |
CN102488088A (en) * | 2011-11-14 | 2012-06-13 | 龙岩新奥生物科技有限公司 | Medium-chain fatty glyceride and application thereof in microcapsules |
CN102550817A (en) * | 2011-12-31 | 2012-07-11 | 厦门金达威集团股份有限公司 | Functional oil microencapsulation and manufacturing method thereof |
CN102860506A (en) * | 2012-08-08 | 2013-01-09 | 辽宁省大连海洋渔业集团公司 | Krill oil microcapsual powder and its preparation method |
CN106172876A (en) * | 2014-09-09 | 2016-12-07 | 长谷川香料株式会社 | For giving powdered oil compositions and the adding method thereof of breast local flavor |
CN107105743A (en) * | 2014-10-08 | 2017-08-29 | 雅培制药有限公司 | Alimentation composition comprising oxidizable components and water soluble plant extract |
-
2017
- 2017-10-24 CN CN201710996359.2A patent/CN107712900A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269310A (en) * | 2008-05-06 | 2008-09-24 | 大连赛诺微囊技术有限公司 | Method for preparing cold water dispersion type microcapsule powder |
CN101647512A (en) * | 2009-06-17 | 2010-02-17 | 新奥(厦门)农牧发展有限公司 | Polyphyly fat mixture for feeding animals and microcapsule applying mixture |
WO2011026612A1 (en) * | 2009-09-02 | 2011-03-10 | Lipofoods, S.L. | Microcapsules containing salts for food products |
CN102488088A (en) * | 2011-11-14 | 2012-06-13 | 龙岩新奥生物科技有限公司 | Medium-chain fatty glyceride and application thereof in microcapsules |
CN102550817A (en) * | 2011-12-31 | 2012-07-11 | 厦门金达威集团股份有限公司 | Functional oil microencapsulation and manufacturing method thereof |
CN102860506A (en) * | 2012-08-08 | 2013-01-09 | 辽宁省大连海洋渔业集团公司 | Krill oil microcapsual powder and its preparation method |
CN106172876A (en) * | 2014-09-09 | 2016-12-07 | 长谷川香料株式会社 | For giving powdered oil compositions and the adding method thereof of breast local flavor |
CN107105743A (en) * | 2014-10-08 | 2017-08-29 | 雅培制药有限公司 | Alimentation composition comprising oxidizable components and water soluble plant extract |
Non-Patent Citations (1)
Title |
---|
何东平等: "《油脂工厂设计手册 上》", 31 August 2012, 湖北科学技术出版社 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108578370B (en) * | 2018-04-19 | 2021-01-19 | 大连医诺生物股份有限公司 | Lutein/lutein ester microparticles and preparation method thereof |
CN108578370A (en) * | 2018-04-19 | 2018-09-28 | 大连医诺生物股份有限公司 | Lutein/lutein ester particle and preparation method thereof |
CN108967987A (en) * | 2018-06-20 | 2018-12-11 | 漯河双汇生物工程技术有限公司 | A kind of garlicky essence of blending type and preparation method thereof |
CN109007838A (en) * | 2018-07-25 | 2018-12-18 | 长沙浩然医疗科技有限公司 | A kind of functional health care food and preparation method thereof of lecithin norcholesterol |
CN109090360A (en) * | 2018-08-10 | 2018-12-28 | 湖南普菲克生物科技有限公司 | A kind of coconut oil micro-capsule fatty powder and the application in the big perinatal period daily ration of sow |
CN109380700A (en) * | 2018-11-08 | 2019-02-26 | 天津科技大学 | A kind of galic essential oil microcapsules and preparation method thereof |
CN109259228A (en) * | 2018-11-12 | 2019-01-25 | 陕西海斯夫生物工程有限公司 | A kind of raw ketone weight-reducing microcapsule powder of full element and preparation method thereof |
CN109315786A (en) * | 2018-11-26 | 2019-02-12 | 荣海生物科技有限公司 | A kind of MLCT microcapsules and preparation method thereof containing small-molecular peptides |
CN109566772A (en) * | 2018-11-30 | 2019-04-05 | 北京诺康达医药科技股份有限公司 | Micro mist and preparation method thereof containing fish oil linseed oil safflower oil |
CN109924488A (en) * | 2019-04-25 | 2019-06-25 | 璐炬. | A kind of acer truncatum seed and linseed compound cryosar Ultramicro-powder microcapsule preparation method |
CN110419736A (en) * | 2019-04-25 | 2019-11-08 | 河北康睿达脂质有限公司 | A kind of middle backbone lipid composition preparation method of mammary gland disease nutrition treatment |
CN110419736B (en) * | 2019-04-25 | 2022-07-05 | 河北康睿达脂质有限公司 | Preparation method of medium-long chain structure lipid composition for nutritional treatment of breast diseases |
CN111150087A (en) * | 2019-12-31 | 2020-05-15 | 西昌市正中食品有限公司 | Embedding wall material and microcapsule tartary buckwheat extract and preparation process thereof |
CN111357835A (en) * | 2020-03-03 | 2020-07-03 | 中国食品发酵工业研究院有限公司 | Sea buckthorn seed oil microcapsule rich in dietary fiber and preparation method thereof |
US11110140B1 (en) * | 2020-04-10 | 2021-09-07 | Daniel Lilly | Medicinal food products and methods for producing said products |
CN111466448A (en) * | 2020-04-14 | 2020-07-31 | 劲牌持正堂药业有限公司 | Preparation method of high-water-solubility fructus cannabis extract |
CN111925771A (en) * | 2020-08-18 | 2020-11-13 | 福建农林大学 | Pressure-responsive room-temperature curing wood adhesive and preparation method thereof |
CN112075630A (en) * | 2020-08-24 | 2020-12-15 | 武汉星辰现代生物工程有限公司 | Natural carotene microcapsule and preparation method thereof |
CN112450285A (en) * | 2020-10-21 | 2021-03-09 | 武汉轻工大学 | Oxidation-resistant pumpkin seed oil capsule and preparation method thereof |
CN112716014A (en) * | 2020-12-22 | 2021-04-30 | 浙江远大生物科技有限公司 | Preparation method of unsaturated fatty acid microcapsule |
CN112913934A (en) * | 2021-03-24 | 2021-06-08 | 固始县豫申粮油工贸有限公司 | Preparation method of powdered medium-long carbon chain triglyceride rice oil |
CN113303463A (en) * | 2021-05-31 | 2021-08-27 | 苏州品宝食品有限公司 | Method for manufacturing healthy medium chain triglyceride powder based on microcapsule technology |
CN113812552B (en) * | 2021-09-01 | 2023-12-26 | 江南大学 | Total nutrient solid beverage |
CN114271496A (en) * | 2021-12-15 | 2022-04-05 | 河北东康乳业有限公司 | Diabetes type vegetable oil diglyceride microcapsule fat powder and preparation method thereof |
CN114287624A (en) * | 2021-12-27 | 2022-04-08 | 黑龙江八一农垦大学 | Composite protein emulsion gel and production method thereof |
CN114287624B (en) * | 2021-12-27 | 2023-11-03 | 黑龙江八一农垦大学 | Composite protein emulsion gel and production method thereof |
CN114521655A (en) * | 2022-01-27 | 2022-05-24 | 华南理工大学 | Intestinal tract probiotic promoter containing medium-long chain triglyceride in almond oil and preparation method and application thereof |
CN114304689A (en) * | 2022-02-10 | 2022-04-12 | 宝得瑞(湖北)健康产业有限公司 | Preparation method of high-oil-loading microcapsule powder without adding synthetic emulsifier |
CN115337880A (en) * | 2022-07-15 | 2022-11-15 | 纽斯葆广赛(广东)生物科技股份有限公司 | Pumpkin seed oil microcapsule and preparation method and application thereof |
CN115337880B (en) * | 2022-07-15 | 2024-06-04 | 纽斯葆广赛(广东)生物科技股份有限公司 | Pumpkin seed oil microcapsule and preparation method and application thereof |
WO2024076917A1 (en) * | 2022-10-03 | 2024-04-11 | Innovative Flours, Llc | Protein-complexed mct oil, method of manufacture, and food products made therefrom |
WO2024076911A1 (en) * | 2022-10-03 | 2024-04-11 | Innovative Flours, Llc | Composite flour, method of manufacture, and food products made therefrom |
US11963536B1 (en) | 2022-10-03 | 2024-04-23 | Innovative Flours, Llc | Composite flour, method of manufacture, and food products made therefrom |
US12011004B2 (en) | 2022-10-03 | 2024-06-18 | Innovative Flours, Llc | Composite plant-MCT flour, method of manufacture, and food products made therefrom |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107712900A (en) | Long-chain fat acid glyceride microcapsules and its production method in a kind of feature | |
Khalid et al. | A comprehensive characterisation of safflower oil for its potential applications as a bioactive food ingredient-A review | |
CN103444911A (en) | Medicinal and edible health care blending oil | |
CN100562254C (en) | A kind of plant blend oil | |
JPH044298B2 (en) | ||
CN106962506A (en) | A kind of ready-mixed oil and preparation method thereof | |
CN1899052A (en) | Method for preparing milk powder for regulating blood fat | |
CN105076490A (en) | Low-cholesterol nutrient health-care peanut oil and preparing method thereof | |
CN102100260A (en) | Yeast grease and preparation method and application thereof | |
CN104673490A (en) | Refining method of rice bran oil | |
CN107441217A (en) | A kind of Orally taken emulsion rich in alpha linolenic acid and preparation method thereof | |
CN105124002A (en) | Method for preparing nutrient supplement peony seed oil microcapsule | |
CN103651949A (en) | Health-maintaining and weight-losing type blending oil | |
CN101530138A (en) | Medium-long chain health care prandial oil | |
CN101099562A (en) | Omega-3 unsaturated fatty acids appetizer oil and producing method and application thereof | |
CN104170989A (en) | Tea oil milk drink and preparation method thereof | |
CN101999652A (en) | Blood fat-reducing health-care food and preparation method thereof | |
CN105145870A (en) | Pre-seasoned peanut oil convenient to cook and preparation method of pre-seasoned peanut oil | |
CN107996726A (en) | Strange Asia seed vegetable protein beverage and preparation method thereof | |
CN108651635A (en) | Has effects that the nutrition-balanced health-care edible oil of brain boosting and supplementing | |
CN109845840B (en) | Preparation method of saturated fatty acid and medium-long chain fatty acid structured lipid | |
JP2020536572A (en) | Manufacturing method of monoacylglyceride oil and foods containing monoacylglyceride oil | |
CN114391582A (en) | Protein solid beverage and preparation method thereof | |
CN107853534A (en) | A kind of preparation method of opacifiers | |
CN108402467A (en) | A kind of composition and its application, food and drug for improving ectogenous fat utilization rate improving tumor patient nutritional need |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180223 |